Targeted delivery of dystrophin has the potential to be a highly effective treatment for Duchenne muscular dystrophy Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announces that it has secured £655,000 in funding from Duchenne ...